These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 32416867)

  • 21. Design and preparation of the class B G protein-coupled receptors GLP-1R and GCGR for
    Wang H; Hu W; Liu D; Wüthrich K
    FEBS J; 2021 Jul; 288(13):4053-4063. PubMed ID: 33369025
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Human GLP-1 receptor transmembrane domain structure in complex with allosteric modulators.
    Song G; Yang D; Wang Y; de Graaf C; Zhou Q; Jiang S; Liu K; Cai X; Dai A; Lin G; Liu D; Wu F; Wu Y; Zhao S; Ye L; Han GW; Lau J; Wu B; Hanson MA; Liu ZJ; Wang MW; Stevens RC
    Nature; 2017 Jun; 546(7657):312-315. PubMed ID: 28514449
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Structural insights into the activation of GLP-1R by a small molecule agonist.
    Ma H; Huang W; Wang X; Zhao L; Jiang Y; Liu F; Guo W; Sun X; Zhong W; Yuan D; Xu HE
    Cell Res; 2020 Dec; 30(12):1140-1142. PubMed ID: 32724086
    [No Abstract]   [Full Text] [Related]  

  • 24. Structural insight into antibody-mediated antagonism of the Glucagon-like peptide-1 Receptor.
    Hennen S; Kodra JT; Soroka V; Krogh BO; Wu X; Kaastrup P; Ørskov C; Rønn SG; Schluckebier G; Barbateskovic S; Gandhi PS; Reedtz-Runge S
    Sci Rep; 2016 May; 6():26236. PubMed ID: 27196125
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Structural Determinants of Binding the Seven-transmembrane Domain of the Glucagon-like Peptide-1 Receptor (GLP-1R).
    Yang D; de Graaf C; Yang L; Song G; Dai A; Cai X; Feng Y; Reedtz-Runge S; Hanson MA; Yang H; Jiang H; Stevens RC; Wang MW
    J Biol Chem; 2016 Jun; 291(25):12991-3004. PubMed ID: 27059958
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Novel insights into the dynamics behavior of glucagon-like peptide-1 receptor with its small molecule agonists.
    Girdhar K; Dehury B; Kumar Singh M; Daniel VP; Choubey A; Dogra S; Kumar S; Mondal P
    J Biomol Struct Dyn; 2019 Sep; 37(15):3976-3986. PubMed ID: 30296922
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Discovery of V-0219: A Small-Molecule Positive Allosteric Modulator of the Glucagon-Like Peptide-1 Receptor toward Oral Treatment for "Diabesity".
    Decara JM; Vázquez-Villa H; Brea J; Alonso M; Srivastava RK; Orio L; Alén F; Suárez J; Baixeras E; García-Cárceles J; Escobar-Peña A; Lutz B; Rodríguez R; Codesido E; Garcia-Ladona FJ; Bennett TA; Ballesteros JA; Cruces J; Loza MI; Benhamú B; Rodríguez de Fonseca F; López-Rodríguez ML
    J Med Chem; 2022 Apr; 65(7):5449-5461. PubMed ID: 35349261
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Transmembrane α-helix 2 and 7 are important for small molecule-mediated activation of the GLP-1 receptor.
    Rye Underwood C; Møller Knudsen S; Schjellerup Wulff B; Bräuner-Osborne H; Lau J; Knudsen LB; Peters GH; Reedtz-Runge S
    Pharmacology; 2011; 88(5-6):340-8. PubMed ID: 22134089
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A Duplexed High-Throughput Screen to Identify Allosteric Modulators of the Glucagon-Like Peptide 1 and Glucagon Receptors.
    Morris LC; Days EL; Turney M; Mi D; Lindsley CW; Weaver CD; Niswender KD
    J Biomol Screen; 2014 Jul; 19(6):847-58. PubMed ID: 24525870
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Landmark studies on the glucagon subfamily of GPCRs: from small molecule modulators to a crystal structure.
    Yang DH; Zhou CH; Liu Q; Wang MW
    Acta Pharmacol Sin; 2015 Sep; 36(9):1033-42. PubMed ID: 26279155
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Minireview: Signal bias, allosterism, and polymorphic variation at the GLP-1R: implications for drug discovery.
    Koole C; Savage EE; Christopoulos A; Miller LJ; Sexton PM; Wootten D
    Mol Endocrinol; 2013 Aug; 27(8):1234-44. PubMed ID: 23864649
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Identification of N-Terminally Diversified GLP-1R Agonists Using Saturation Mutagenesis and Chemical Design.
    Longwell CK; Hanna S; Hartrampf N; Sperberg RAP; Huang PS; Pentelute BL; Cochran JR
    ACS Chem Biol; 2021 Jan; 16(1):58-66. PubMed ID: 33307682
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Structural basis for GLP-1 receptor activation by LY3502970, an orally active nonpeptide agonist.
    Kawai T; Sun B; Yoshino H; Feng D; Suzuki Y; Fukazawa M; Nagao S; Wainscott DB; Showalter AD; Droz BA; Kobilka TS; Coghlan MP; Willard FS; Kawabe Y; Kobilka BK; Sloop KW
    Proc Natl Acad Sci U S A; 2020 Nov; 117(47):29959-29967. PubMed ID: 33177239
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cryo-electron microscopy structure of the glucagon receptor with a dual-agonist peptide.
    Chang R; Zhang X; Qiao A; Dai A; Belousoff MJ; Tan Q; Shao L; Zhong L; Lin G; Liang YL; Ma L; Han S; Yang D; Danev R; Wang MW; Wootten D; Wu B; Sexton PM
    J Biol Chem; 2020 Jul; 295(28):9313-9325. PubMed ID: 32371397
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Characterization of signal bias at the GLP-1 receptor induced by backbone modification of GLP-1.
    Hager MV; Clydesdale L; Gellman SH; Sexton PM; Wootten D
    Biochem Pharmacol; 2017 Jul; 136():99-108. PubMed ID: 28363772
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Identification of a novel allosteric GLP-1R antagonist HTL26119 using structure- based drug design.
    O'Brien A; Andrews SP; Baig AH; Bortolato A; Brown AJH; Brown GA; Brown SH; Christopher JA; Congreve M; Cooke RM; De Graaf C; Errey JC; Fieldhouse C; Jazayeri A; Marshall FH; Mason JS; Mobarec JC; Okrasa K; Steele KN; Southall SM; Teobald I; Watson SP; Weir M
    Bioorg Med Chem Lett; 2019 Oct; 29(20):126611. PubMed ID: 31447084
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Polymorphism and ligand dependent changes in human glucagon-like peptide-1 receptor (GLP-1R) function: allosteric rescue of loss of function mutation.
    Koole C; Wootten D; Simms J; Valant C; Miller LJ; Christopoulos A; Sexton PM
    Mol Pharmacol; 2011 Sep; 80(3):486-97. PubMed ID: 21616920
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ligand-Receptor Interactions and Machine Learning in GCGR and GLP-1R Drug Discovery.
    Mizera M; Latek D
    Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33920024
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A Dual GLP-1/GIP Receptor Agonist Does Not Antagonize Glucagon at Its Receptor but May Act as a Biased Agonist at the GLP-1 Receptor.
    Al-Zamel N; Al-Sabah S; Luqmani Y; Adi L; Chacko S; Schneider TD; Krasel C
    Int J Mol Sci; 2019 Jul; 20(14):. PubMed ID: 31330984
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Abolishing β-arrestin recruitment is necessary for the full metabolic benefits of G protein-biased glucagon-like peptide-1 receptor agonists.
    Hinds CE; Peace E; Chen S; Davies I; El Eid L; Tomas A; Tan T; Minnion J; Jones B; Bloom SR
    Diabetes Obes Metab; 2024 Jan; 26(1):65-77. PubMed ID: 37795639
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.